Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Orally Disintegrating Tablet Market Evolve in Terms of Growth and Size by 2029?

The market size for orally disintegrating tablets has been expanding robustly over recent years. The market is set to escalate from a value of $14.88 billion in 2024 to $16.20 billion in 2025, realizing a compound annual growth rate (CAGR) of 8.8%. Factors contributing to growth during the historic period include a surge in pediatric and geriatric populations, a rising incidence of central nervous system disorders, amplified demand for easy-to-use drug delivery methods, an increase in dysphagia cases, and a heightened utilization of outpatient care.

Anticipations are high for a significant expansion of the orally disintegrating tablet market in the coming years; it is projected to surge to a valuation of $22.53 billion in 2029, representing a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth over the projected period include the escalating crisis of chronic diseases, a rise in self-medicated treatment, the growing influence of telemedicine and e-pharmacies, increasing emphasis on individualized treatment, mounting demand for vegan and allergen-friendly options, and a growing senior citizen demographic. Key trends throughout this anticipated period entail the creation of multi-drug orally disintegrating tablets, fusion with digital health platforms, enhancements in packaging for better stability and mobility, taste-alteration technologies, as well as ongoing progress in formulation technology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

What factors are expected to fuel Orally Disintegrating Tablet market growth in the coming years?

The growth of the orally disintegrating tablet market is expected to be driven by a growing prevalence of neurological disorders. These disorders affect the brain and peripheral nerves disrupting the normal operations of the nervous system. The increasing incidence of such disorders is primarily due to prolongation in human life span as disorders like Alzheimer’s and Parkinson’s begin to manifest more frequently with age. By facilitating easier and quicker drug administration, orally disintegrating tablets have proven beneficial for those with neurological conditions, especially those suffering from swallowing difficulties known as dysphagia, or cognitive impairments. They also enhance the effectiveness of therapy by encouraging proper medication adherence and ensuring appropriate timing of dosages. For instance, data from March 2023, as provided by the Alzheimer’s Association, an American voluntary health organization, shows that in 2023, around 6.7 million Americans aged 65 and above are living with Alzheimer’s dementia. The projection for 2060 stands at an escalated figure of 13.8 million. Such rising rates of neurological disorders are propelling the growth of the orally disintegrating tablet market.

What Are The Key Findings From The Segmentation Analysis Of The Orally Disintegrating Tablet Market?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Other PPIs

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

What Long-Term Trends Are Likely To Affect The Orally Disintegrating Tablet Market?

Leading businesses in the orally disintegrating tablet market are concentrating on innovative drug formulation, including patient-centered drug delivery systems, to boost treatment adherence and better patient outcomes. A patient-centered drug delivery system essentially involves the development and administration of medication that is simpler and more comfortable for patients, thus enhancing their treatment experience and compliance. For example, in May 2025, Viatris Inc., a healthcare firm based in the US, introduced Gen-Clozapine orally disintegrating tablets (ODT) to the Canadian market as a novel therapy for treatment-resistant schizophrenia. It brings several distinctive attributes, establishing it as a valuable addition to managing treatment-resistant schizophrenia in Canada. Being the first clozapine orally disintegrating tablet (ODT) in the country, it offers a patient-friendly solution that dissolves rapidly in the mouth without the need for water, proving helpful for those with trouble swallowing or issues with adherence. The product comes in various strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), facilitating flexible and accurate dose adjustment based on the specific needs of each patient. Using clozapine, the sole approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation helps conform to existing treatment guidelines.

What Are The Most Active Companies In The Orally Disintegrating Tablet Market Today?

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions, KalVista Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Which Regional Markets Are Attracting The Most Investment In Orally Disintegrating Tablet?

North America was the largest region in the orally disintegrating tablet market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model